Please login to the form below

Not currently logged in
Email:
Password:

Marschall Runge joins Lilly’s board of directors

Will serve on the pharma company's Science and Technology, and Public Policy and Compliance Committees

Lilly Marschall Runge Lilly has added academic experience to its board of directors with the appointment of Dr Marschall Runge, who is executive dean for the School of Medicine at the University of North Carolina (UNC).

Dr Runge will serve on Lilly's Science and Technology Committee and the Public Policy and Compliance Committee, where he will use his years of experience in medicines research and healthcare to provide advice on company strategies.

This experience includes his current role at UNC, where he provides overall academic and clinical leadership for the School of Medicine.

Dr Runge also currently serves as principal investigator and director of the North Carolina Translational and Clinical Sciences (NC TraCS), one of 60 medical research institutions that form a national consortium to improve the way biomedical research is conducted across the US.

His previous positions include faculty member at Harvard's Massachusetts General Hospital and associate professor of medicine at Emory University.

“Dr Runge brings to the Lilly board a broad background in healthcare, with extensive experience as a practicing physician, clinical researcher, and dean of a major academic medical institution,” said Dr John Lechleiter, Lilly's chairman, president and CEO.

“His appreciation of the importance of scientific research, coupled with his first-hand experience in patient care, will help Lilly deliver on its commitment to discover and develop innovative medicines that make a difference for patients in need."

30th August 2013

From: Research

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
CSafe Global

CSafe Global is the only global provider of a full line of cold chain solutions and is the world’s largest...

Latest intelligence

Delivering true value: what does it mean for KAM in cancer care?
Lisa Alderson, Business Development Director at Wilmington Healthcare, explores the challenges that pharma’s KAM teams face in engaging with the NHS and how they must evolve...
Pharma M&A
Pharma funding and M&A in 2020
Why pharma M&A has continually bucked the trend...
Behaviour change through medical education: How can we turn aspiration into reality?
Practical, evidence-based insights into a CME process that aims to effect measurable behaviour change...

Infographics